Alnylam Pharma (ALNY) Posts Smaller-than-Expected Q1 Loss

Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.22), $0.25 better than the analyst estimate of ($1.47). Revenue for the quarter came in at $21.9 million versus the consensus estimate of $30.15 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c
• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24